Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00560989 · ClinicalTrials.gov registry record

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

A clinical trial of Sarcoidosis and Berylliosis, sponsored by National Jewish Health.

Completed
Registry status
400
Enrollment target
1
Study location

NCT00560989 is a study of Sarcoidosis and Berylliosis that has completed, run by National Jewish Health. The registered enrollment target is 400 participants, below the 2,150-participant average among 21 other Sarcoidosis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00560989, a study of Sarcoidosis and Berylliosis, has completed, sponsored by National Jewish Health.

COMPLETED
Registry status
400 participants
Enrollment target
1
Study location

Study Summary

Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses to the disease. Genetic variations may make some people more susceptible to developing CBD or sarcoidosis. This study will identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.

Conditions Studied

Study Locations (1)

Colorado

  • National Jewish Medical and Research Center - Denver

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2007-03
Est. Completion 2007-03

Sponsor

National Jewish Health

83 total trials

What the Registry Record Tells You About NCT00560989

The ClinicalTrials.gov registry entry for NCT00560989 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,150-participant average among 21 other Sarcoidosis trials with a reported enrollment target (81% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sarcoidosis appearing as the primary indexed condition, and to 0 interventions.

NCT00560989 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00560989 about?

NCT00560989 is a clinical study titled "Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis". Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses ...

What is the current status of trial NCT00560989?

This trial is currently completed. The enrollment target is 400 participants. The study started on 2007-03. Estimated completion is 2007-03.

What conditions does trial NCT00560989 study?

This clinical trial studies the following conditions: Sarcoidosis, Berylliosis.

Who is sponsoring clinical trial NCT00560989?

This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00560989 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.